ArticleImmunity, inflammation and disease2026
Identification of Ferroptosis-Related Hub Genes and Immune Infiltration Landscape in Chronic Kidney Disease via Bioinformatics and Experimental Verification.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a serious global health problem with increasing incidence. Ferroptosis plays a crucial role in kidney diseases, but limited studies have elucidated the mechanism and role of ferroptosis in CKD.
methodsCKD data sets and ferroptosis-related genes were acquired from the Gene Expression Omnibus (GEO) database and FerrDB V2. By integrating bioinformatics including weighted gene coexpression network analysis (WGCNA), enrichment analyses, protein-protein interaction (PPI) network and GeneMANIA analysis, ferroptosis-related hub genes were identified in CKD. Validation of hub genes was conducted using an external data set, and diagnostic potential capability was evaluated through receiver operating curve (ROC) analysis. Subsequently, the relationship between hub genes and clinical traits was performed using Nephroseq v5 database. Gene set enrichment analysis (GSEA) of hub genes was performed. The CIBERSORT algorithm was employed to examine the infiltration of 22 distinct immune cell types in CKD. Western blotting, RT-qPCR and HPA database were utilized to further validate the role of NFE2L2, NNMT and GDF15 in CKD.
resultsBy integrating bioinformatics including WGCNA, PPI, and GeneMANIA, 7 hub genes were identified including NNMT, GDF15, ACSL1, DLD, NFE2L2, PARP1, and NR4A1. These hub genes have been validated in the validation set and clinical correlation analysis established a clear link between hub gene expression and renal function deterioration. ROC analysis demonstrated excellent diagnostic efficacy. GSEA indicated that these hub genes affect CKD progress or prognosis through the posttranscriptional modifications and transport of pathogenic factors, immune dysfunction, and cell cycle dysregulation. The CKD samples exhibited elevated levels of CD8
conclusionOur study confirms NNMT, GDF15, ACSL1, DLD, NFE2L2, PARP1, and NR4A1 as significantly upregulated biomarkers associated with ferroptosis in CKD progression, suggesting their potential as novel targets for CKD diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.